The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Daniel Pollyea | ASH 2018 | Venetoclax in combination with HMAs in patients with AML ineligible for intensive therapy
Featured:
Daniel PollyeaAt the 2018 American Society of Hematology meeting, Daniel Pollyea from the University of Colorado School of Medicine, Denver, US, talks about data from an open-label, phase Ib, dose escalation and expansion trial, studying the safety and efficacy of venetoclax in combination with decitabine or azacitidine.
Venetoclax in combination with either azacitidine or decitabine led to high rates of rapid and deep responses that were durable in patients with acute myeloid leukemia (AML) ineligible for standard induction chemotherapy.
Venetoclax in combination with HMAs in patients with AML ineligible for intensive therapy